Alpha 2.0
Login Register
» Articles » PMID: 36406835

Hyponatraemia in Patients on Immune Checkpoint Inhibitors

Overview
Journal Ther Adv Endocrinol Metab
Specialty Endocrinology
Date 2022 Nov 21
PMID 36406835
Authors
Stavroula A Paschou
Evanthia Kassi
Theodora Psaltopoulou
Affiliations
Soon will be listed here.
Citing Articles

Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine.

Longhitano E, Muscolino P, Lo Re C, Ferrara S, Cernaro V, Gembillo G Cancers (Basel). 2023; 15(6).

PMID: 36980777 PMC: 10046877. DOI: 10.3390/cancers15061891.

References
1.
Husebye E, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M . Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022; 187(6):G1-G21. PMC: 9641795. DOI: 10.1530/EJE-22-0689. View
2.
Husebye E, Pearce S, Krone N, Kampe O . Adrenal insufficiency. Lancet. 2021; 397(10274):613-629. DOI: 10.1016/S0140-6736(21)00136-7. View
3.
Chang L, Barroso-Sousa R, Tolaney S, Hodi F, Kaiser U, Min L . Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev. 2018; 40(1):17-65. PMC: 6270990. DOI: 10.1210/er.2018-00006. View
4.
Paschou S, Liontos M, Eleftherakis-Papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K . Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. Front Oncol. 2022; 12:847917. PMC: 8987508. DOI: 10.3389/fonc.2022.847917. View
5.
Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View